Luye Pharma Group Ltd (LUP) — Capital Reinvestment Ratio

Latest as of June 2021: 1.01x

Luye Pharma Group Ltd (LUP) has a Capital Reinvestment Ratio of 1.01x as of June 2021, meaning it reinvests 1% of its operating cash flow (€274.59 Million) in capital expenditures (€278.10 Million). See debt-free asset ratio of Luye Pharma Group Ltd to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

1.01x
Capex / Operating Cash Flow

Operating Cash Flow

€274.59 Million
EUR

Capital Expenditures

€278.10 Million
EUR

Data as of

Jun 2021
Most recent filing

Luye Pharma Group Ltd Capital Reinvestment Ratio (2016–2025)

This chart tracks Luye Pharma Group Ltd's Capital Reinvestment Ratio across 10 annual periods. Check Luye Pharma Group Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Luye Pharma Group Ltd (2016–2025)

Year-by-year Capital Reinvestment Ratio for Luye Pharma Group Ltd from 2016 to 2025. For live market cap and broader valuation context, see Luye Pharma Group Ltd (LUP) market capitalisation.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2025 0.56x €1.78 Billion €1.00 Billion ▼ -94.5%
2024 10.18x €167.76 Million €1.71 Billion ▲ +1294.4%
2023 0.73x €1.60 Billion €1.17 Billion ▲ +3.8%
2022 0.70x €1.65 Billion €1.16 Billion ▼ -76.9%
2021 3.05x €182.37 Million €556.20 Million ▲ +354.9%
2020 0.67x €1.03 Billion €692.81 Million ▼ -4.6%
2019 0.70x €1.42 Billion €999.34 Million ▲ +0.9%
2018 0.70x €1.05 Billion €728.16 Million ▲ +32.3%
2017 0.53x €964.10 Million €507.32 Million ▼ -2.4%
2016 0.54x €592.03 Million €319.14 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow